No profile data available.
GeneDx Holdings Corp. (WGS) is a healthcare company in the medical testing laboratories industry, based in Stamford, United States, with about 1,300 full-time employees.
It reported revenue of $427.54 million for fiscal year 2025, up 40.0% from fiscal year 2024, and net income of -$21.02 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $114.44 million, up 11.4% from a year before. Its largest business segment, Gene Dx, brought in 99% of segment revenue in fiscal year 2025. Its market capitalization was $2.01 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
GeneDx Holdings reported $427.54 million in revenue for fiscal year 2025, up 40.0% from $305.45 million in fiscal year 2024. In Q2 2026 revenue was $114.44 million.
Gene Dx, with $423.09 million or 99% of segment revenue in fiscal year 2025. Next: Fabric Genomics and Legacy Sema4 (1%).
$2.01 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (medical testing laboratories) include Quest Diagnostics Incorporated (DGX), Labcorp Holdings Inc. (LH), NeoGenomics, Inc. (NEO), Opko Health, Inc. (OPK).